Risk score for the exclusion of arrhythmic events in arrhythmogenic right ventricular cardiomyopathy at first presentation.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
01 09 2019
Historique:
received: 08 03 2019
revised: 25 04 2019
accepted: 29 04 2019
pubmed: 21 5 2019
medline: 8 5 2020
entrez: 21 5 2019
Statut: ppublish

Résumé

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetically determined heart muscle disorder associated with an increased risk of life-threatening arrhythmias in some patients. Risk stratification remains challenging. Therefore, we sought a non-invasive, easily applicable risk score to predict sustained ventricular arrhythmias in these patients. Cohort of Patients who fulfilled the 2010 ARVC task force criteria were consecutively recruited. Detailed clinical data were collected at baseline and during follow up. The clinical endpoint was a composite of recurrent sustained ventricular arrhythmias and hospitalization due to ventricular arrhythmias. Multivariable logistic regression was used to develop models to predict the arrhythmic risk. A cohort including patients from other registries in UK, Canada and Switzerland was used as a validation population. One hundred and thirty-five patients were included of whom 35 patients (31.9%) reached the endpoint. A model consisting of filtered QRS duration on signal-averaged ECG, non-sustained VT (NSVT) on 24 h-ECG, and absence of negative T waves in lead aVR on 12‑lead surface ECG was able to predict arrhythmic events with a sensitivity of 81.8%, specificity of 84.0% and a negative predictive value of 95.5% at the first presentation of the disease. This risk score was validated in international ARVC registry patients. A risk score consisting of a filtered QRS duration ≥117 ms, presence of NSVT on 24 h-ECG and absence of negative T waves in lead aVR was able to predict arrhythmic events at first presentation of the disease.

Identifiants

pubmed: 31104822
pii: S0167-5273(19)31229-X
doi: 10.1016/j.ijcard.2019.04.090
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

100-105

Subventions

Organisme : British Heart Foundation
ID : RG/13/19/30568
Pays : United Kingdom

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Annina S Vischer (AS)

Medical Outpatient Department, University Hospital Basel, Basel, Switzerland. Electronic address: annina.vischer@usb.ch.

Silvia Castelletti (S)

Istituto Auxologico Italiano, IRCCS, Center for Cardiac Arrhythmias of Genetic Origin, Milan, Italy.

Petros Syrris (P)

Institute of Cardiovascular Science, University College of London, London, UK.

Rachel Bastiaenen (R)

Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK; Cardiology Clinical Academic Group, St George's University Hospitals NHS Foundation Trust, London, UK.

Chris Miles (C)

Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK; Cardiology Clinical Academic Group, St George's University Hospitals NHS Foundation Trust, London, UK.

Deniz Akdis (D)

Department of Cardiology, University Heart Center, Zurich, Switzerland.

Kris Denhaerynck (K)

University of Basel, Department of Public Health, Institute of Nursing Science, Basel, Switzerland.

Daniel Jacoby (D)

Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.

Ardan M Saguner (AM)

Department of Cardiology, University Heart Center, Zurich, Switzerland.

Andrew D Krahn (AD)

Division of Cardiology, University of British Columbia, Vancouver, BC, Canada.

Elijah R Behr (ER)

Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK; Cardiology Clinical Academic Group, St George's University Hospitals NHS Foundation Trust, London, UK.

William J McKenna (WJ)

Institute of Cardiovascular Science, University College of London, London, UK.

Antonios Pantazis (A)

Cardiomyopathy Service, Royal Brompton Hospital, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH